Compare Nutanix Inc (NTNX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Smith & Nephew plc — how do they compare? Nutanix Inc trades at $64.65 (market cap $17.39B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Nutanix Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.65% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| NTNX | SNN | |
|---|---|---|
Market Cap | $17.39B | $12.54B |
Sector | Technology | Health |
52-Week High | $81.12 | $38.70 |
52-Week Low | $34.41 | $28.73 |
Enterprise Value | $16.90B | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $64.65, up 0.29% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.36, maintaining a streak of earnings surprises. Revenue growth accelerated to $2.7B in 2026 with net profit margin expanding to 10.03%, while institutional interest remains strong with recent acquisitions by Arrowstreet Capital and CalPERS.
Outlook remains positive with 62.5% analyst buy ratings and a $57.80 consensus target, though current price exceeds this level. Key risks include supply chain constraints affecting hardware lead times and competitive pressure in cloud infrastructure. The stock's elevated P/E of 67.71 requires continued execution to justify valuation, with Q2 2026 earnings on August 26th serving as near-term catalyst.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
